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ABSTRACT
Thyroid associated ophthalmopathy is an autoimmune disorder affecting the orbital and periorbital tissues. Hyperthyroidism
is commonly associated with thyroid associated ophthalmopathy, however in 5% to 10% of cases it is euthyroid. Genetic,
environmental and endogenous factors play a role in the initiation of the thyroid ophthalmopathy. Smoking has been identified
as the strongest risk factor for the development of the disorder. The pathogenesis involves activation of both humoral and cell
mediated immunity with subsequent production of gycoaminoglycans, hyaluronic acid resulting in oedema formation, increase
extraocular mass and adipogenesis in the orbit. The natural history of the disease progresses from active to inactive fibrotic
stage over a period of years. Diagnosis is mainly clinical and almost all patients with ophthalmopathy exhibit some form of
thyroid abnormality on further testing. Treatment is based on the clinical severity of the disease. Non-severe cases are
managed by supportive measures to reduce the symptomatology and severe cases are treated by either medical or surgical
decompression. Rehabilitative surgery is done for quiescent disease to reduce diplopia and improve cosmesis.
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INTRODUCTION
Thyroid associated ophthalmopathy (TAO) is also known as,
thyroid eye disease (TED), Graves’ ophthalmopathy/
orbitopathy (GO), dysthyroid ophthalmopathy, thyrotoxic
exophthalmos and other terms. It is an autoimmune process
which affects the thyroid gland, orbital and periorbital tissue
and uncommonly the pretibial skin or digits (thyroid acropachy).
The individual components can occur together or separately.
It is the most frequent extrathyroidal manifestation of Graves’
disease. Although TAO is often associated with
hyperthyroidism, it may occur in primary hypothyroidism,
Hashimoto’s thyroiditis, and sometimes in euthyroid
individuals.1-3 The incidence and prevalence of Graves’
disease is 0.1% and 1% respectively. The clinical signs include
widening of the palpebral fissure, eye lid retraction, lid lag,
conjunctival congestion, chemosis, proptosis, corneal
exposure, restrictive myopathy and optic neuropathy. In
majority of cases the ocular manifestations are mild, and
severe form of the disease affects 3% to 5% of individuals.4
METHODOLOGY
All our reference articles were obtained from Pubmed. The
key words for search were thyroid ophthalmopathy, thyroid
orbitopathy, thyroid associated ophthalmopathy, ocular
manifestations of thyroid, ocular features of Graves’ disease,
thyroid eye disease, and Graves’ ophthalmopathy etc. We
used the MeSH database and journal database for our search
and our search limits were articles in English and age above
1 year.
FREQUENCY
The exact incidence of ophthalmopathy is not clear. The
prevalence of TAO (thyroid associated ophthalmopathy)  in
patients with GD (Graves’ disease) in Caucasian population
is generally thought to be between 25% and 50%.5,6  Bartley7
reported, in a population- based setting in USA, an annual
incidence rate of 16 cases per 100,000 population per year
for women, and 2.9 cases for men. In Malaysia, Lim et al8
